Corsalex’s mission is to identify, fund, and develop promising projects to treat C9orf72 ALS/FTD.

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating adult-onset neurodegenerative diseases. Genetic analysis has revealed the hexanucleotide repeat expansion (HRE) disorder C9orf72 as the most common cause of familial ALS/FTD (C9-ALS/FTD). 


Corsalex is a joint venture between KCK and Panorama Research. Led by Dr. James Larrick, a biomedical entrepreneur with an international reputation and over 30-year career in biotechnology, and backed by KCK,  the Company hopes to spur innovation and advance meaningful interventions for this devastating disease. 

Biotechnology

Health Care

Life Sciences

Venture Capital

Corsalex, Inc.

Corsalex, Inc.'s headquarters in Cupertino, United States

Corsalex, Inc.

Org chart

Teams

Offices

Similar companies